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ABSTRACT
Objective The bodily distress syndrome (BDS) checklist 
has proven to be useful in the diagnostic categorisation 
and as screening tool for functional somatic disorders 
(FSD). This study aims to investigate whether the BDS 
checklist total sum score (0–100) can be used as a 
measure of physical symptom burden and FSD illness 
severity.
Design Cross- sectional.
Setting Danish general population, primary care and 
specialised clinical setting.
Participants A general population cohort (n=9656), a 
primary care cohort (n=2480) and a cohort of patients 
with multiorgan BDS from specialised clinical setting 
(n=492).
Outcome measures All data were self- reported. Physical 
symptoms were measured with the 25- item BDS checklist. 
Overall self- perceived health was measured with one 
item from the 36- item Short- Form Health Survey (SF-36). 
Physical functioning was measured with an aggregate 
score of four items from the SF-36/SF-12 scales ‘physical 
functioning’, ‘bodily pain’ and ‘vitality’. Emotional distress 
was measured with the mental distress subscale (SCL-
8) from the Danish version of the Hopkins Symptom 
Checklist-90. Illness worry was measured with the six- 
item Whiteley Index.
Results For all cohorts, bifactor models established that 
despite some multidimensionality the total sum score of 
the BDS checklist adequately reflected physical symptom 
burden and illness severity. The BDS checklist had 
acceptable convergent validity with measures of overall 
health (r=0.25–0.58), physical functioning (r=0.22–0.58), 
emotional distress (r=0.47–0.62) and illness worry 
(r=0.36–0.55). Acceptability was good with a low number 
of missing responses to items (<3%). Internal consistency 
was high (α ≥0.879). BDS score means varied and 
reflected symptom burden across cohorts (13.03–46.15). 
We provide normative data for the Danish general 
population.
Conclusions The BDS checklist total sum score can be 
used as a measure of symptom burden and FSD illness 
severity across settings. These findings establish the 
usefulness of the BDS checklist in clinics and in research, 
both as a diagnostic screening tool and as an instrument 
to assess illness severity.
INTRODUCTION
Persistent physical symptoms (PPS) are 
common in medical settings and in the 
general population.1–4 The symptoms present 
across a continuum from one or a few momen-
tary to numerous symptoms from multiple 
locations in the body. Having a high number 
of symptoms has been associated with poor 
health, poor functional status and increased 
healthcare use.5–9 Hence, assessment of the 
burden of PPS is valuable in both clinical care 
and in research.
For this purpose, self- reported symptom 
questionnaires are frequently used, which 
are manageable, non- invasive tools. Several 
screening questionnaires exist: the Hopkins 
Symptom Checklist,10 the Patient Health 
Questionnaire-15 (PHQ-15),11 the Somatic 
Symptom Scale-8 (SSS-8),12 13 the brief form 
of the Giessen Subjective Complaints List 
(GBB-8)14 and others.15–17 However, the 
existing questionnaires measure PPS without 
considering the well- known aggregation of 
such symptoms into symptom clusters, and 
hence without acknowledgement of the real 
structure of PPS as they occur in both the 
community and in clinical setting.18–21
When PPS occur in the absence of (other) 
physical or mental conditions, or when they 
cause individual suffering and functional 
Strengths and limitations of this study
 ► The study included data from three cohorts and set-
tings: a general population, patients from primary 
care and patients from a specialised setting.
 ► Well- validated measures were used to determine 
convergent validity.
 ► All included cohorts had large sample sizes.
 ► Only self- reported measures were included.
 ► Convergent validity was not investigated with other 
measures of physical symptom burden.
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limitations beyond what could be expected based on such 
diseases, they constitute the very core of the disorders 
captured under the umbrella definition of functional 
somatic disorders (FSD). FSD covers both specialty- 
specific syndrome diagnoses such as fibromyalgia, irri-
table bowel and chronic fatigue, and also their pendants 
in psychosomatic medicine, somatoform and somatic 
symptom disorders.22
In contrast to the above- mentioned specialty- specific 
diagnoses, the proposed research diagnosis bodily 
distress syndrome (BDS) covers a broader range of func-
tional somatic symptoms, ranging from a few symptoms 
with some effect on functioning to severe and disabling 
FSD.18 19 21 Hence, BDS provides the opportunity to assess 
and distinguish between conditions persisting as mono-
syndromatic or multi- syndromatic and still within the 
same framework of diagnostic approach.21 23 The diag-
nostic construct was developed in a sample of patients 
from primary and secondary care, and the 30- item BDS 
checklist emerged.18 The BDS checklist was confirmed in 
a new sample of primary care patients where the short-
ened 25- item BDS checklist was developed.19 Subse-
quently, the construct of the BDS checklist has been 
confirmed in general population samples as well.21 24 The 
BDS checklist presents symptoms grouped in four clus-
ters—cardiopulmonary, gastrointestinal, musculoskeletal 
and general symptoms—and its usefulness and the prop-
erties used for diagnostic categorisation into no BDS, 
single/oligo- organ BDS type and multiorgan BDS type 
have been established.19 21 24 A major strength of the BDS 
checklist is its usefulness both as a screening and as a diag-
nostic tool within clinical practice and within epidemio-
logical research18 19 21 23; however, the total BDS sum score 
has not yet been validated as a measure to assess symptom 
burden and illness severity.
This study aims to explore whether the BDS checklist 
can be used as a continuous score to measure symptom 
burden (ie, in those individuals who may fall under the 
diagnostic threshold or what we believe to be clinically 
relevant) and illness severity (in those individuals fulfilling 
the diagnostic criteria for FSD). In order to elicit the BDS 
checklist’s usability across settings, its structural validity 
and psychometric properties will be explored in three 
different populations: the general population, patients in 
primary care and patients in a specialised clinical setting.
METHODS
Population
This cross- sectional study included baseline data from 
three cohorts:
Cohort 1 is a general population cohort (DanFunD, 
n=9656, response rate=33.7%) established with the 
purpose to investigate and unravel the epidemiology of 
FSD.25 The cohort was obtained from the Danish Central 
Personal Register and drawn as a random sample of adult 
Danish background population aged 18–69 years. Partici-
pants lived in 10 municipalities in the south- western part 
of the greater Copenhagen area. All participants were 
born in Denmark.
Cohort 2 is a cohort of primary care patients (KOS, 
n=2480, response rate=59.5%) established in order to 
investigate contact and disease patterns in general prac-
tice.26 Participants were included consecutively from 388 
general practitioners from the Central Denmark Region. 
Included participants were 18 years or older and had 
completed a health- related face- to- face consultation with 
their general practitioner.
Cohort 3 consists data from a specialised clinical 
setting at the Research Clinic for Functional Disor-
ders and Psychosomatics, Aarhus University Hospital in 
Denmark (STreSS-3, STreSS-4, STreSS-5, n=492, response 
rate=100%).27–31
These cohorts had been part of a group of studies 
with the shared aim of investigating new treatments for 
patients aged 20 years or older with multiorgan BDS.
Measures
Self- reported data on physical symptoms, overall health, 
physical health, mental health and illness worry were 
included. The measures and the data were not completely 
consistent across the three included cohorts.
Physical symptoms were assessed with the Danish 
version of the 25- item BDS checklist (online supple-
mental appendix A).19 21 The checklist asks ‘during the last 
(specific time frame) have you been bothered by’, followed 
by a list of 25 symptoms comprising the four symptom 
clusters of BDS. The BDS checklist measures symptoms 
on a 5- point rating scale from 0 (‘not at all bothersome’) 
to 4 (‘a lot bothersome’). We calculated the sum score by 
adding the single item scores from the 25 items (ranging 
from 0 to 100). The time frame covered was 12 months 
for the general population cohort and 4 weeks for the 
other two cohorts.
Overall health was assessed with a single item from the 
36- item Short- Form Health Survey (SF-36),32 estimating 
self- perceived health on a 5- point rating scale from ‘excel-
lent’ to ‘poor’. Higher score on this item indicates poorer 
health. No specific time frame was surveyed in neither of 
the cohorts.
Physical functioning was measured with a shortened 
version of an aggregate score of the SF-36 subscales ‘phys-
ical functioning’, ‘bodily pain’ and ‘vitality’.30 32–34 The 
shortened version consisted of four items (two items from 
the ‘physical function’ subscale, one item from the ‘bodily 
pain’ subscale and one item from the ‘vitality’ subscale) 
which are part of the SF-12, addressing limitations in 
moderate and strenuous activities due to physical health 
and pain interference. For each item a z- score was calcu-
lated using mean and SD from the general Danish popu-
lation. The mean of the z- scores from the three subscales 
results in an aggregate z- score. This is then transformed 
into a t- score (mean=50, SD=10). Higher scores indi-
cate better physical health. We tested the correlation 
of the t- score of the shortened version aggregate score 
against the full SF-36 aggregate score in cohort 3, and the 
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correlation was high (Spearman’s r=0.89, 95% CI 0.87 to 
0.91). Unfortunately, it was not possible to investigate the 
convergent validity to the aggregate score in the data of 
the primary care cohort because we had limited access to 
the data. These analyses were therefore only performed 
in the general population cohort and the cohort from 
specialised clinical setting. The time frame covered was 
4 weeks for both cohorts.
Emotional distress was measured with the mental 
distress subscale (SCL-8) from the Danish version of the 
Hopkins Symptom Checklist (SCL-90).35 36 SCL-8 consists 
of eight items addressing impairment of overall worries, 
depression and anxiety. Answers were calculated as mean 
scores from a scale ranging from 0 (‘not at all bother-
some’) to 4 (‘a lot bothersome’). Higher scores indicate 
higher emotional distress. The time frame covered was 
1 week for the general population cohort and 4 weeks for 
the two other cohorts.
Illness worry was measured with the revised version of 
the six- item Whiteley Index (Whiteley-6- R),37 addressing 
respondents’ fear of being ill and whether they attri-
bute current bodily sensations to somatic illness. (In the 
primary care sample, one of the items in the Whiteley-6- R 
‘Do you worry about the possibility that you suffer from 
an illness you have heard or read about?’ was expressed 
as ‘Do you worry about the possibility that you suffer from 
an illness?’) Answers were calculated as mean scores from 
a scale ranging from 0 (‘not at all bothersome’) to 4 (‘a 
lot bothersome’). Higher scores indicate higher health 
anxiety. The time frame covered was 12 months for the 
general population cohort and 4 weeks for the two other 
cohorts.
Validation procedure and statistical analyses
The analyses for the current study were performed 
according to the COSMIN (Consensus- based Standards 
for the selection of health Measurement Instrument) 
framework.38
All statistical analyses were performed using STATA 
V.16.0,39 except for the structural equation modelling 
which was performed using Mplus V.8.1.40 Construct 
validity was tested by means of structural validity and 
convergent validity. Structural validity was tested with 
confirmatory factor analysis (CFA) with WLSMV 
(weighted least squares means and variance adjusted) 
estimation due to the categorical responses for all items.40 
We wanted to test if it was permissible to model the BDS 
checklist as unidimensional despite previous evidence 
of some multidimensionality.18 19 21 24 Furthermore, we 
wanted to test if the raw total BDS sum score would be an 
adequate reliable measure of the general factor (BDS). 
Therefore, four different CFAs were performed: (1) a 
one- level one- factor model; (2) a one- level four- factor 
model, using factors resembling the four BDS symptom 
clusters previously reported19 21; (3) a two- level four- factor 
model, representing a second- order common factor 
(BDS) underlying the four BDS symptom clusters; and 
(4) a bifactor CFA, reflecting each symptom to load on a 
general factor (BDS) and on one of the four specific BDS 
symptom clusters. Illustrations of the four types of CFAs 
are displayed in online supplemental appendix B.
In all CFAs, model fit was assessed as follows: a root 
mean square error of approximation <0.05 indicates 
very good fit, 0.05–0.08 indicates a good fit and ≥0.08 
indicates a poor fit. Comparative fit index and Tucker- 
Lewis fit index at 0.90–0.95 indicate an acceptable fit and 
levels >0.95 indicate a good fit. A standardised root mean 
square residual <0.08 indicates good fit.41
Convergent validity was tested with Spearman’s 
correlations, and associations between the BDS check-
list and overall health (one item from SF-36),32 physical 
function (an aggregate score of four items from the 
SF-36),42 emotional distress (SCL-8)35 and illness worry 
(Whiteley-6- R)37 were obtained. Based on previous liter-
ature,12 14 15 17 43 we hypothesised that the BDS checklist 
would show moderate convergent validity (r=0.40–0.60) 
with the four measures, and we expected lower correla-
tions in the sample from specialised setting. Expected 
differences on the BDS checklist with one- unit difference 
from SCL-8, the four- item aggregate score for physical 
functioning and Whiteley-6- R were estimated with linear 
regression.
The BDS checklist item and scale characteristics, that is, 
item means (SD), sum score means, score distribution and 
item total correlation, corrected for overlap, and aspects 
of acceptability, that is, percentage of missing items, were 
examined and computed as descriptive statistics for each 
of the three samples. Internal consistency was measured 
with Cronbach’s α coefficients, where values between 0.7 
and 0.95 are acceptable.38
For all three cohorts, written informed consent was 
obtained from each participant before entering the 
studies.25–31 The STreSS-3 trial in cohort 3 was registered 
with  ClinicalTrials. gov (NCT01518634) and EudraCT 
(2011-004294-87), while the STreSS-4 trial was registered 
with  ClinicalTrials. gov (NCT01518647).
Patient and public involvement
It was not appropriate to involve patients or the public 
in the design, or conduct, or reporting or dissemination 
plans of our research.
RESULTS
Sample characteristics
The median age of the general population sample was 
54 years (IQR: 44–64) and 53.9% were female. In the 
primary care sample, the mean age was 54.3 years (SD: 
17.5) and 62.5% were female. In the sample from special-
ised setting, the mean age was 39.4 years (SD: 8.8) and 
81.1% were female.
Structural validity
The one- level one- factor model showed unacceptable fit 
indices in all three cohorts (table 1).









pen: first published as 10.1136/bm






4 Petersen MW, et al. BMJ Open 2020;10:e042880. doi:10.1136/bmjopen-2020-042880
Open access 
Fit indices for the one- level four- factor model which 
has been confirmed in previous studies19 21 and the two- 
level four- factor model showed more acceptable fits. 
These models revealed correlations between the four 
BDS symptom clusters and loadings from an under-
lying BDS factor to the four BDS symptom clusters 
that may imply a bifactor model. Good fit indices were 
seen for the bifactor model. Hence, a model reflecting 
a general factor (BDS) and four independent factors 
(BDS symptom clusters) all explaining the variance of 
the 25 symptoms in the BDS checklist was confirmed 
(figure 1). Loadings from the general BDS factor were 
generally higher than loadings from the four symptom 
clusters; for the general population cohort this was the 
case for 72% of symptoms, in the primary care cohort 
it accounted for 64% of symptoms, and in the special-
ised setting it accounted for 52% of symptoms. Loading 
from the general BDS factor was smaller than loading for 
six symptoms from the four symptom clusters (frequent 
loose bowel movements, diarrhoea, pain in the arms and legs, 
Figure 1 Illustration and factor loadings from the bifactor model across all three cohorts. BDS, bodily distress syndrome; CP, 
cardiopulmonary; Gen., general population; GI, gastrointestinal; GS, general symptoms; MS, musculoskeletal; Prim., primary 
care; Spec., specialised clinical setting.
Table 1 Goodness of fit parameters from the CFA models
RMSEA 95% CI CFI TLI SRMR X2 df P value
One- level one- factor CFA
  General population 0.111 0.110 to 0.112 0.723 0.697 0.09 32 743.1 275 <0.0001
  Primary care 0.419 0.147 to 0.151 0.697 0.67 0.119 15 126.5 275 <0.0001
  Specialised setting 0.149 0.144 to 0.153 0.621 0.586 0.115 3261.5 275 <0.0001
One- level four- factor CFA
  General population 0.062 0.061 to 0.063 0.914 0.905 0.052 10 290.96 269 <0.0001
  Primary care 0.082 0.08 to 0.084 0.91 0.9 0.067 4666.85 269 <0.0001
  Specialised setting 0.091 0.086 to 0.096 0.862 0.846 0.076 1355.96 269 <0.0001
Two- level four- factor CFA
  General population 0.061 0.06 to 0.062 0.917 0.908 0.052 9951.02 271 <0.0001
  Primary care 0.08 0.078 to 0.082 0.914 0.905 0.068 4482.39 271 <0.0001
  Specialised setting 0.089 0.084 to 0.093 0.867 0.853 0.076 1315.04 271 <0.0001
Bifactor CFA
  General population 0.048 0.046 to 0.049 0.954 0.944 0.04 5680.8 250 <0.0001
  Primary care 0.053 0.051 to 0.055 0.965 0.958 0.042 1977.4 250 <0.0001
  Specialised setting 0.059 0.054 to 0.065 0.945 0.934 0.051 681.1 250 <0.0001
Bold indicates good or acceptable fit between the specified model and the observed model in the data.
χ2, likelihood ratio test; CFA, confirmatory factor analysis; CFI, comparative fit index; RMSEA, root mean square error of approximation; 
SRMR, standardised root mean square residual; TLI, Tucker- Lewis fit index.
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muscular aches or pain, pain in the joints and concentration 
difficulties) in all three cohorts.
Convergent validity
In the general population sample, our hypothesis was met 
for all measures. The BDS checklist had moderate conver-
gent validity compared with the SF-36 item for overall 
health (r=0.48, 95% CI 0.46 o 0.49, p<0.0001), the four- 
item aggregate score for physical health (r=−0.58, 95% CI 
−0.59 to −0.56, p<0.0001), the SCL-8 for emotional 
distress (r=0.52, 95% CI 0.51 to 0.54, p<0.0001) and the 
Whiteley-6- R for illness worry (r=0.53, 95% CI 0.52 to 0.55, 
p<0.0001). The expected difference on the BDS checklist 
with one- unit difference from the four- item aggregate 
score was −0.80 (95% CI −0.82 to −0.78), 12.26 (95% CI 
11.89 to 12.63) with SCL-8, and 8.93 (95% CI 8.64 to 9.21) 
with Whiteley-6- R (online supplemental appendix C).
For the primary care sample, our hypothesis was 
met for all measures as well; however, for some of the 
measures, the association was stronger than hypothesised. 
We found moderate convergent validity compared with 
the SF-36 item for overall health (r=0.58, 95% CI 0.56 to 
0.61, p<0.0001), the SCL-8 for emotional distress (r=0.62, 
95% CI 0.59 to 0.64, p<0.0001) and the Whiteley-6- R for 
illness worry (r=0.55, 95% CI 0.52 to 0.58, p<0.0001). 
The expected difference on the BDS checklist with one- 
unit difference was 10.60 (95% CI 10.08 to 11.12) with 
SCL-8 and 10.01 (95% CI 9.44 to 10.59) with Whiteley-6- R 
(online supplemental appendix C).
For the sample from specialised setting, our hypothesis 
about the correlations being weaker was met. Moderate 
convergent validity was seen with emotional distress 
(r=0.47, 95% CI 0.40 to 0.54, p<0.0001), while weaker 
correlations were seen for overall health (r=0.25, 95% CI 
0.17 to 0.33, p<0.0001), physical health (r=−0.22, 95% CI 
−0.30 to −0.12, p<0.0001) and illness worry (r=0.36, 
95% CI 0.28 to 0.43, p<0.0001). The expected difference 
on the BDS checklist with one- unit difference from the 
four- item aggregate score for physical health was −0.41 
(95% CI −0.56 to −0.26), 7.92 (95% CI 6.65 to 9.18) with 
SCL-8, and 5.88 (95% CI 4.58 to 7.17) with Whiteley-6- R 
(online supplemental appendix C).
Response distributions and acceptability
The BDS checklist item and scale characteristics are 
displayed in table 2. Item means varied from 0.15 to 1.09 
in the general population sample, from 0.31 to 1.53 in the 
primary care sample, and from 0.81 to 3.34 in the sample 
from specialised setting. While the item with the lowest 
mean varied across samples, the item ‘excessive fatigue’ 
had the highest mean value in all samples. Most item total 
correlations, corrected for overlap, exceeded 0.4.
Internal consistency was good in all three samples: 
α=0.887 in the general population sample, α=0.908 in 
the primary care sample and α=0.879 in the sample from 
specialised setting.
The BDS score distribution differed across samples 
(figure 2), as did total sum score means; it was lowest in 
the general population (13.03, SD: 10.36) and highest in 
specialised setting (46.15, SD: 15.91) (table 2). Accept-
ability was good, and the number of missing responses 
was generally low in the general population (total 0.6%) 
and specialised setting (total 0.2%), while it was slightly 
higher in primary care (total 2.7%).
The BDS total sum scores were grouped into five cate-
gories: 0–20, 21–40, 41–60, 61–80 and 81–100. The vast 
majority of the general population respondents (96.6%) 
and primary care patients (90%) scored below 41, while 
this was only the case for a smaller fraction of patients 
from specialised setting (38.7%) (table 3). Data from 
each of the three samples and for all three samples pooled 
together are shown as cumulative percentages across sex 
and age groups in online supplemental appendix D.
DISCUSSION
Principal findings
This is the first study to establish that, despite some multi-
dimensionality, the 25- item BDS checklist can be used 
as a continuous score to measure symptom burden and 
illness severity in the general population, in primary 
care and in specialised settings. Used as a total sum score 
ranging from 0 to 100, the BDS checklist had acceptable 
convergent validity with measures of overall health, phys-
ical health, emotional distress and illness worry. Internal 
consistency was good in all three cohorts (α ≥0.879), 
as was acceptability. Thus, the BDS checklist may work 
as a simple symptom checklist but also as a diagnostic 
screening tool for use in clinical work and in research 
across different settings.
We found the symptom ‘excessive fatigue’ to have the 
highest mean value in all three cohorts. This is in line 
with a recent German population- based study finding 
‘tiredness’ to be one of the leading symptoms.44
The three cohorts differed in the number of symp-
toms that had higher loadings on the general BDS factor 
than on the four symptom clusters, ranging from 72% 
of symptoms in the general population cohort to 52% 
in the cohort from specialised clinical setting. The latter 
group contains patients with long- standing and severe 
FSD. In this group, the symptom load is high and specific 
symptom clusters may therefore stand out compared with 
the less affected participants from the general population 
with a more scattered symptom picture.
Previous studies have argued that the best fitting model 
for the BDS checklist was a one- level four- factor model 
(online supplemental appendix B).19 21 24 However, 
the objectives of these studies were to confirm the BDS 
checklist as a case- finding instrument in other samples, 
with inspiration from the original studies in which the 
concept of the BDS checklist was developed and initially 
tested.18 19 In the current study, we have taken it several 
steps further and tested various structural equation 
models in three different populations at the same time. 
The following are the indicators of a bifactor model: (1) 
if the intercorrelation between the subscales in the CFA 
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exceeds 0.3; (2) if loading on the first- order factors on 
the second- order factors exceeds 0.545; and (3) if the ratio 
between the first and second eigenvalues exceeds 3.46 
All parameters were fulfilled in the general population 
cohort and in the primary care cohort. For the cohort 
from specialised setting, the ratio between the first and 
Table 2 Item and scale characteristics
Item













Palpitations/heart pounding 0.9 0.45 (0.74) 0.427 3.1 0.61 (0.93) 0.544 0.2 1.46 (1.25) 0.48
Precordial discomfort 1.1 0.29 (0.61) 0.41 2.9 0.46 (0.81) 0.517 0.2 1.09 (1.16) 0.391
Breathlessness without 
exertion
1 0.36 (0.71) 0.426 2.9 0.63 (0.99) 0.509 0.2 1.27 (1.25) 0.511
Hyperventilation 1.1 0.15 (0.47) 0.321 3.3 0.37 (0.81) 0.448 0.2 0.93 (1.19) 0.38
Hot and cold sweats 1.2 0.46 (0.80) 0.429 3.2 0.64 (0.96) 0.533 0.2 1.88 (1.35) 0.523
Dry mouth 1.2 0.39 (0.76) 0.432 3.4 0.59 (0.98) 0.501 0.2 1.33 (1.36) 0.442
Frequent loose bowel 
movements
1 0.65 (0.86) 0.403 3.4 0.61 (0.95) 0.391 0.2 1.41 (1.32) 0.357
Abdominal pain 1.4 0.48 (0.76) 0.511 3.5 0.57 (0.90) 0.548 0.2 1.81 (1.22) 0.491
Feeling bloated/full of gas/
distended
1.1 0.74 (0.91) 0.524 2.9 0.78 (1.03) 0.532 0.2 2.09 (1.30) 0.484
Diarrhoea 1.1 0.33 (0.63) 0.387 3.5 0.37 (0.80) 0.361 0.2 0.81 (1.13) 0.348
Regurgitations 1.4 0.43 (0.74) 0.392 3.3 0.35 (0.74) 0.456 0.2 1.05 (1.09) 0.43
Nausea 0.9 0.26 (0.57) 0.465 2.9 0.50 (0.87) 0.564 0.2 1.73 (1.27) 0.402
Burning sensation in the upper 
part of stomach/epigastrium
0.9 0.31 (0.68) 0.441 3.1 0.31 (0.72) 0.483 0.2 1.11 (1.26) 0.512
Pain in the arms or legs 1 0.87 (1.08) 0.538 3.1 1.21 (1.29) 0.563 0.2 2.68 (1.24) 0.472
Muscular aches or pain 1.3 0.98 (1.01) 0.572 3.2 1.30 (1.23) 0.584 0.2 2.96 (1.10) 0.485
Pain in the joints 1.6 0.96 (1.07) 0.49 3.9 1.20 (1.27) 0.56 0.2 2.57 (1.32) 0.491
Feeling of paresis or localised 
weakness
1.4 0.16 (0.55) 0.365 4 0.33 (0.83) 0.46 0.2 1.22 (1.40) 0.481
Backache 1.3 1.00 (1.06) 0.492 3.3 1.21 (1.29) 0.542 0.2 2.49 (1.37) 0.377
Pain moving from one place to 
another
1.4 0.27 (0.71) 0.489 3.8 0.54 (0.99) 0.544 0.2 2.13 (1.48) 0.403
Unpleasant numbness or 
tingling sensations
1.3 0.25 (0.67) 0.41 4 0.34 (0.83) 0.475 0.2 2.00 (1.43) 0.528
Concentration difficulties 0.7 0.60 (0.82) 0.545 2.9 0.85 (1.05) 0.54 0.2 2.53 (1.11) 0.437
Excessive fatigue 0.7 1.09 (1.01) 0.614 2.3 1.53 (1.20) 0.625 0.2 3.34 (0.83) 0.418
Headache 0.8 0.66 (0.89) 0.455 2.8 0.89 (1.08) 0.489 0.2 2.25 (1.22) 0.326
Impairment of memory 0.7 0.60 (0.83) 0.517 2.7 0.80 (1.06) 0.521 0.2 2.29 (1.27) 0.476
Dizziness 0.8 0.34 (0.67) 0.491 2.5 0.58 (0.94) 0.553 0.2 1.75 (1.30) 0.505
Scale
Total scale missing (%) 0.6 2.7 0.2
Mean (SD) 13.03 (10.36) 17.33 (13.79) 46.15 (15.91)
Percentiles
5% 1 2 22
10% 3 3 26
25% 6 7 34
50% (median) 11 14 45
75% 18 24 57
90% 27 37 67
34 45 73
IQR: 25% percentile and 75% percentile.
*Item total correlation, corrected for overlap.
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second eigenvalues was 2.68, but otherwise the parame-
ters were fulfilled. This implies that the results from this 
study do not disqualify results from previous research; 
however, the presence of some multidimensionality is not 
strong enough to disqualify the interpretation of the BDS 
checklist as unidimensional as well.
Correlations between the BDS checklist and self- rated 
measures of overall health, physical health, emotional 
distress and illness worry were generally moderate, 
especially in the general population and primary care 
cohort. This was as expected as previous literature has 
shown the same association between symptom load and 
reduced function.6 7 The difference between the results 
from patients in the specialised settings and from the 
two other populations may be due to the nature of self- 
reported measures, where patients in specialised setting 
still have the opportunity to rate their perceived health 
as excellent even though they have been referred to 
specialised medical care due to invalidating physical 
symptoms. These aspects may result in precision limita-
tions in some settings and may especially be pronounced 
in smaller samples. Furthermore, the distribution of sex 
differs across populations, which may affect the results on 
convergent validity.
Strengths and weaknesses of the study
A major strength of this study is the inclusion of three 
different populations. To our knowledge, this approach 
of testing an instrument and using the same methodology 
in different populations is rare as most other studies 
concerned only one setting at a time.11 12 14 17 Also, the 
sample size within each cohort was large. We conducted 
a thorough validation procedure using different struc-
tural equation models and testing convergent validity to 
several valid measures.
Figure 2 Distribution of the bodily distress syndrome (BDS) total sum score across all three cohorts.








n % n % n %
0–20 7.762 80.4 1.617 65.2 20 4.1
21–40 1.607 16.6 616 24.8 170 34.6
41–60 208 2.2 156 6.3 204 41.5
61–80 18 0.2 23 0.9 87 17.7
81–100 0 0 2 0.1 10 2.0
Missing 61 0.6 66 2.7 1 0.2
More detailed information about the normative data from each 
of the three samples and for all three samples pooled together is 
shown in online supplemental appendix D tables 1–4.
BDS, bodily distress syndrome.
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The weaknesses of the study include the following: Only 
self- reported outcomes were used and data measures were 
not completely consistent across the included cohorts; 
hence, we chose to apply the intersection of items in 
order to gain equivalent proxy measures. We did not have 
the opportunity to compare the BDS checklist with other 
measures of physical symptoms, or for the primary care 
cohort and the cohort from specialised clinical setting 
with physicians’ report. Furthermore, in the linear regres-
sion analysis, the assumption of normality of the residuals 
was not fully met for the primary care cohort and the 
cohort from specialised clinical care, which is why these 
results should be interpreted with caution. Finally, as this 
study had a cross- sectional design, it was not possible to 
evaluate the responsiveness of the BDS checklist.
Difference in results compared with others
To our knowledge, this is the first study to address the 
usefulness of the BDS checklist as a measure of physical 
symptom burden and illness severity. Another symptom 
checklist which has been widely used within primary care 
and general population studies to measure the severity of 
physical symptoms is the PHQ-15.11 17 It consists of 15 items 
concerning some of the symptoms from the same four 
organ systems as the BDS checklist, plus the symptoms 
‘fainting’, ‘sleeping problems’, ‘menstrual problems’ and 
‘sexual pains/problems’ not included in the BDS check-
list. PHQ-15 is scored on a 3- point rating scale from ‘not 
bothered at all’ (0) to ‘bothered a lot’ (2), whereas the 
BDS checklist uses a 5- point rating scale. In one study 
including a sample from the general Swedish population, 
factor analyses of the structural properties of PHQ-15 
showed a four- factor model, but on the basis of a scree test 
plot they finally concluded that only one factor should be 
extracted.47 Other studies found a bifactor model to have 
the best fit to PHQ-15.48 49 Hence, PHQ-15 may have the 
same structural properties as the BDS checklist, but with 
fewer items to take into account as well as fewer response 
categories, which may make it more prone to floor and 
ceiling effects. In a shorter version of PHQ-15, the SSS-8, 
the 3- point rating scale is replaced with a 5- point rating 
option as in the BDS checklist.12 13 50 However, neither the 
PHQ-15 nor the SSS-8 is validated for use as a diagnostic 
categorisation tool for respondents. Other symptom 
questionnaires resembling the same four- factor structure 
and the same five- answer categories as the BDS checklist 
are the 24- item Giessen Subjective Complaints List and 
its newer shortened version with eight items (GBB-8); 
however, they have only been established and used in 
German- speaking countries.14
The BDS checklist is, at present, the only symptom 
checklist providing both diagnostic categorisation and a 
measure of symptom load/illness severity.
Clinical implications
This study provides a self- reported symptom checklist for 
measuring symptom burden and illness severity which 
can be used both as a diagnostic screening tool and as a 
measure of illness severity in large epidemiological studies 
and also in more selected patient samples and severely ill 
patients. Regarding FSD, previous research has suggested 
measures of symptom burden as the primary outcome.33 
However, the current study shows that the BDS checklist 
shows weaker correlation with measures of overall health, 
physical health, emotional distress and illness worry 
in patients from highly specialised setting than in the 
general population and primary care. Hence, a simple 
count of bothersome symptoms may not be adequate 
when dealing with the more severely ill patients, as 
symptom burden may not be the only important domain 
of illness severity—others may be the level of impairment 
and mental morbidity.
Currently, it is unclear whether the BDS total sum score 
presented here reliably captures FSD illness severity than 
the distinction in single versus multiorgan BDS (eg, three 
vs four clusters fulfilled). Nevertheless, a tool which is also 
able to measure the severity of specific symptom clusters 
is helpful in specialised settings, as it is possible to eluci-
date which symptom cluster is experienced most bother-
some by the patients.
Future research and perspectives
In this study we suggest the BDS checklist as a promi-
nent tool as it can be used both as a measure of symptom 
burden and as a diagnostic screening tool for FSD, and we 
argue for its usefulness in both epidemiological and clin-
ical research as well as in clinical practice. However, the 
criterion validity of the self- reported BDS checklist with 
physicians’ established diagnoses, for example, specialty- 
specific syndrome diagnoses and psychiatric diagnoses, is 
yet to be investigated across settings, and future studies 
regarding these aspects would be valuable in order to 
further establish the usefulness of the BDS checklist. 
Moreover, the additional value of counting the number of 
symptom clusters fulfilled in the staging of FSD deserves 
attention. Finally, we need a valid instrument to measure 
change over time, and the responsiveness of the BDS 
checklist sum score is worth exploring.
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